Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer. [PDF]
, 2018 Concurrent chemoradiation (cCRT) with platinum-based chemotherapy is standard-of-care therapy for patients with stage III unresectable non-small cell lung cancer (NSCLC).
Dicker, Adam P., Lu, Bo, McCall, Neal S.
core +1 more source
Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. [PDF]
, 2017 The major development of the past decade in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was the introduction of cetuximab in combination with platinum plus 5-fluorouracil chemotherapy ...
Ana Ferreira Castro +7 more
core +3 more sources
CPT: Pharmacometrics & Systems Pharmacology, 2023 Enrolling patients in immunotherapy clinical trials is becoming increasingly competitive. Virtual clinical trials can help investigators answer key questions despite this.
Timothy Qi, Yanguang Cao
doaj +1 more source
Pembrolizumab for Fanconi anemia with advanced tongue cancer
Otolaryngology Case Reports, 2022 Introduction: With underlying Fanconi Anemia, head and neck cancer treatment options are usually limited due to the chromosome instability. Pembrolizumab plays a vital role in head and neck cancer with recurrence and distant metastases.
Keitaro Nagano +3 more
doaj +1 more source
Diabetes, Metabolic Syndrome and Obesity, 2021 Lili Wu, Bixun Li Department of Integrated Medicine, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, People’s Republic of ChinaCorrespondence: Bixun LiDepartment of Integrated Medicine, Guangxi Medical University Cancer ...
Wu L, Li B
doaj
Gynecologic Oncology Reports, 2022 Uterine endometrial cancer is one of the most common gynecological malignancies worldwide. With relatively few options for late-line therapies for advanced or relapsed endometrial cancer, the use of pretreated therapies may broaden the choice of ...
Kaito Mimura +7 more
doaj +1 more source
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. [PDF]
, 2018 BackgroundMucosal melanoma is an aggressive melanoma with poor prognosis. We assessed efficacy of pembrolizumab in patients with advanced mucosal melanoma in KEYNOTE-001 (NCT01295827), -002 (NCT01704287), and -006 (NCT01866319).MethodsPatients received ...
Arance, Ana S +14 more
core +1 more source
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. [PDF]
, 2020 PurposeImmune checkpoint blockade has improved outcomes across tumor types; little is known about the efficacy of these agents in rare tumors. We report the results of the (nonpancreatic) neuroendocrine neoplasm cohort of SWOG S1609 dual anti-CTLA-4 and ...
Baghdadi, Tareq Al +21 more
core
Immunological backbone of uveal melanoma: is there a rationale for immunotherapy? [PDF]
, 2019 No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors.
Alessandra Cassano +24 more
core +1 more source
Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study [PDF]
, 2018 Purpose: Abemaciclib, a dual inhibitor of cyclin-dependent kinases 4 and 6, has demonstrated preclinical activity in non–small cell lung cancer (NSCLC).
Beckmann, Richard +16 more
core +2 more sources